Bile Duct Cancer
Bile Duct Cancer
Advertisement
Emily MenendezBile Duct Cancer | February 12, 2024
The developed nomogram was found to provide significant diagnostic accuracy with an area under the curve level of 0.882.
Read More
Emily MenendezASCO GI 2024 | February 7, 2024
Meta-analysis data has shown that HAIP combined with systemic chemotherapy can provide a pooled 3-year OS rate of 39.5%.
Amit Mahipal, MDASCO GI 2024 | January 31, 2024
Dr. Amit Mahipal discusses liquid biopsy for advanced cholangiocarcinoma and how it compares to tissue-based testing.
Milind Javle, MDASCO GI 2024 | January 25, 2024
Dr. Milind Javle discusses tinengotinib monotherapy in patients with metastatic cholangiocarcinoma at ASCO GI 2024.
Katy MarshallASCO GI 2024 | January 23, 2024
The most common first-line therapies were gemcitabine and cisplatin.
Katy MarshallASCO GI 2024 | January 23, 2024
The FDA approved futibatinib in 2022 for previously treated patients with advanced CCA and FGFR2 fusions or rearrangements.
Zachary BessetteASCO GI 2024 | January 23, 2024
New research sheds light on the prognostic value of mutations—including FGFR2 and IDH1—in patients with resectable CCA.
Rob DillardGI Cancer | January 12, 2024
Bile duct cancer treatments could be improved by tailored medications that target the levels of a key protein in ...
Rob DillardGI Cancer | January 12, 2024
The findings of a study published in the journal Molecular Cancer Therapeutics exhibits how resistance to a promising ...
Advertisement
Advertisement
Advertisement
Latest News

February 28, 2024